Though there were setbacks on climate change and funding for science this year, there was still plenty of amazing discoveries ...

A preliminary study of people with diabetes suggests that use of glucose-lowering GLP-1 drugs may be linked to a lower risk ...

A new study suggests popular GLP-1 drugs, like Ozempic and Zepbound, may not lower cancer risk as some had hoped.

Scientists in Sweden have created a new pill designed to help the body burn fat and control blood sugar in a different way ...

We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...

MBX Biosciences, Inc. is rated a Buy, driven by canvuparatide's once-weekly dosing advantage in hypoparathyroidism. Learn ...

AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about ...

Scientists in Sweden have created a new pill designed to help the body burn fat and control blood sugar in a different way than popular GLP-1 drugs, like Ozempic. While injectable GLP-1s work by ...

Key Takeaways A recent NAD decision underscores that advertising compounded drugs in a way that implies they share the benefits of FDA-approved medications will likely be deemed deceptive by ...

GLP-1 side effects like constipation and muscle mass loss can lead to uncomfortable pelvic floor symptoms like bladder leakage and painful sex.

Doctors say the class of medications that includes Ozempic and Zepbound still offers health benefits for people with diabetes ...

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Industry experts ...